ReACT Therapeutics’ Post

In the business of drug development, deals can be just as important as scientific breakthroughs. Many of today’s most lucrative medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Enbrel, might not have become so without mergers and acquisitions. The end of the last decade brought record highs in pharmaceutical M&A as larger companies turned again and again to young biotechs for innovation. Often, these deals focused on cancer, rare diseases and immune system disorders — areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market.

Biotech M&A is picking back up. Here are the latest deals. "In the business of drug development, deals can be just as important as scientific breakthroughs. Many of today’s most lucrative medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Enbrel, might not have become so without mergers and acquisitions." #biopharma #biotech #healthcare #ma Read more 👇

#fundingalert 💼Company: HEPHAISTOS-Pharma 💰Funding: €4.5 Million ⚡Round: Seed 👥Investors: Elaia, xista science ventures, the Fondation Fournier-Majoie and Noshaq. HEPHAISTOS-Pharma is a preclinical biotech company developing the next generation of #immunostimulants against cancer, revolutionizing immune stimulation targeting innate immunity with a unique technology for intravenous administration, opening the way to metastatic and hard-to-treat indications. This seed round will mainly #finance the industrialization of drug production and regulatory toxicity studies to file for the CTA in Europe. HEPHAISTOS already has a lot of preclinical data in many cancer indications, but they plan to generate new additional data in monotherapy against unmet medical needs and in combination with promising drugs from other pharmaceutical companies. Frederic CAROFF, Florian Denis, Martine Caroff, Alexey Novikov Read more - https://lnkd.in/gYkPH4mH To share your startup story write us on - contact@startuprise.co.uk #HEPHAISTOSPharma #biotechstartup #revolutionizing #monotherapy #pharmaceutical #funding #fundingnews #news #startup #startupnews #startuprise

In the business of drug development, deals can be just as important as scientific breakthroughs. Many of today’s most lucrative medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Enbrel, might not have become so without mergers and acquisitions. The end of the last decade brought record highs in pharmaceutical M&A as larger companies turned again and again to young biotechs for innovation. Often, these deals focused on cancer, rare diseases and immune system disorders — areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market. 2021 and 2022 were much quieter for dealmaking, as new challenges and then rising interest rates weighed on negotiations. But there are signs of a rebound, with a flurry of dealmaking to close out 2023. Pharma companies are keen to expand in areas like obesity, while stocking up on newer technologies like antibody-drug conjugates. Even neuroscience, which large drugmakers previously abandoned, is drawing investment again.

Alumis, an 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 on the cusp of 𝐏𝐡𝐚𝐬𝐞 𝟑, has secured $𝟐𝟓𝟎𝐌 𝐢𝐧 𝐚 𝐬𝐡𝐫𝐮𝐧𝐤𝐞𝐧 𝐈𝐏𝐎. The Bay Area startup sold 𝟏𝟑.𝟏𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 𝐚𝐭 $𝟏𝟔 𝐞𝐚𝐜𝐡 to fund the late-stage testing of its lead 𝐓𝐘𝐊𝟐 𝐝𝐫𝐮𝐠, studies of a second asset in neuroinflammatory conditions, and preclinical projects. While the IPO was smaller than initially projected, an additional 𝟐.𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 were sold in a concurrent private placement. With $𝟑𝟒𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐥𝐥𝐨𝐜𝐚𝐭𝐞𝐝 toward clinical development, Alumis aims to create a next-gen immunology treatment, facing competition from Bristol Myers Squibb’s Sotyktu and Takeda’s TAK-279. Alumis has spent heavily on R&D, with $𝟏𝟑𝟕 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐥𝐚𝐬𝐭 𝐲𝐞𝐚𝐫 𝐚𝐧𝐝 $𝟏𝟎𝟏 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐. The company, led by Martin Babler, hopes to buck the trend of biotechs trading below their IPO price. https://lnkd.in/eK_H6kda #Biotech #Immunology #IPO #Pharma #HealthcareInnovation

Stories making headlines today in the biopharma industry: Biotech firm Boundless Bio is on the verge of an estimated $88.4 million IPO. Supported by investments from ARCH and Bayer, the company is currently conducting Phase 1 cancer trials of two oral small molecules. The proceeds from the IPO are slated to uphold the firm's activities until H2 2026. In other news, a group of ex-Prometheus Biosciences executives have reunited with a vision to launch Mirador Therapeutics. Through a significantly funded Series A round, which raised $400 million, the group of over 13 investors led by ARCH Venture Partners has set Mirador on course to become the largest privately funded biotech firm this year. Mirador's mission is to leverage precision medicine for the diagnosis and treatment of a wide spectrum of immune and inflammatory diseases, with an initial focus on gastrointestinal, lung, and skin conditions. It wasn't all great news in the biotech sector, though. Pharma giant Roche experienced a disappointing result when its autoimmune disease drug Enspryng did not live up to its projected success despite meeting its primary endpoint in Phase 3 trials for generalized myasthenia gravis. On the flip side, this result gives a positive nudge to argenx, Johnson & Johnson, and Immunovant, who are all developing or have launched their respective gMG treatments. In an attempt to improve efficiency and address various challenges, Bayer is implementing a restructuring plan that involves reducing its pharmaceutical leadership team by half. This significant change is a part of a more comprehensive approach to handling issues such as debt, lawsuits from the Monsanto acquisition, and losing exclusivity for key treatments. Meanwhile, skincare leader Galderma is steering towards what could be one of the largest IPOs in Europe this year. Set at a high-end share price of $59.31, the IPO is poised to value the company at $2.6 billion. Along with its beloved consumer brands, Galderma's nemolizumab, an il-31 antibody, is currently under FDA priority review for treating prurigo nodularis-induced itch. #biotech #IPO #healthcareinvestment #drugdevelopment #pharma #biotech #topstories #biodatastudio

🔬Messaginglab and Degron Therapeutics Partnered on a $1.2B Collaboration Announcement - With Big Results 🧬 We're thrilled to have collaborated with Degron Therapeutics - an emerging leader in the discovery of small molecule, molecular glue degrader drugs - on their recent press release announcing their $1.2B collaboration with Takeda. Molecular glue degraders are small molecule drugs that act as adhesives by bringing a disease target protein to another protein called E3 ligase, which is a component of a protein degradation machinery. As a result, the disease target protein is “tagged” as trash and degraded in the cell.   This approach has the potential to target previously undruggable proteins, opening new avenues for treating challenging diseases in cancer, inflammation, neurodegenerative and other disorders. Messaginglab's Impact: 💡Translating Difficult Science: We simplified the complexity of molecular glues to help Degron reach a broader audience. Our approach resonated widely for investors, partners, and the public. 💡Amplifying Media Presence: Through targeted outreach, we secured coverage in 20 top life science and pharma publications, including Biocentury, BioWorld, Chemical & Engineering News, and Fierce Biotech. This expanded visibility positioned Degron as a key player in biotech. 💡Crafting a Compelling Corporate Narrative: Beyond the $1.2B deal, we highlighted Degron's mission to revolutionize drug discovery. We created an emotional connection by focusing on the impact on patients' lives, elevating Degron's story above financial metrics. 💡Showcasing Thought Leadership: We positioned Degron's co-founder and CEO, Lily Zou, as a visionary leader. Her quotes and media accessibility added a human touch to the company's technological breakthroughs, building trust and credibility. 💡Driving Meaningful Engagement: Our success went beyond metrics. We focused on generating high-quality media coverage that sparked conversations among key stakeholders in the biotech community. The Power of Partnership: We're proud to have been a part of this groundbreaking work. Our collaboration with Degron Therapeutics showcases Messaginglab's ability to elevate complex science through strategic communication. #MediaRelations #BiopharmaNews

🎉 Big News in Biotech! 🧬 Pfizer, a global pharmaceutical leader, has just inked a monumental 15-year lease for their oncology division in San Diego, marking the region's largest biotech transaction in over a year. This move into the Torrey View office and lab campus by Pfizer emphasizes the ongoing expansion and innovation in cancer therapy research. 🏢💡 As part of Breakthrough Properties’ development, this 230,000-square-foot lease brings the campus to full occupancy before its completion, showcasing the vibrant future of biotech in San Diego, the nation's third-largest biotech hub. 🌟 This lease symbolizes a significant boost in the biotech sector, amidst a time when life science deals are seeking momentum. It reflects the industry's shift towards major research and development efforts in areas like cancer, diabetes, and more. 📈🔬 San Diego continues to attract global pharmaceutical giants, fostering advancements and potentially life-saving therapies. Let's celebrate this leap forward in biotech innovation and the promising developments it heralds for healthcare. 🎗️ For more details on this, check out the full article here: https://lnkd.in/gQMqwkTe (Note: Article is behind a Members only login). . . . . #AJGeorgeResimercial #CommercialRealEstateSanDiego #ResimercialRealEstate #ResimercialRealtor #RealEstateTransactions #Biotech #Pfizer #HealthcareIndusty #HealthcareInnovation #SanDiegoBiotech

#fundingalert 💼Company: Pathios Therapeutics 💰Funding: €23.4 Million ⚡Round: Series B  👥Investors: Bristol Myers Squibb, Canaan and Brandon Capital. Launched in 2017, Pathios is a drug discovery and development company focused on translating innovative science into new medicines. Pathios was founded by a team of experienced biotech and pharmaceutical industry professionals, entrepreneurs, and clinicians. Proceeds from the raise will be used to support the continued development of Pathios’ unique approach to cancer immunotherapy focused on the inhibition of GPR65, a novel target that has been genetically associated with a range of immunologically-mediated diseases. Tom McCarthy, Stuart Hughes, Shelley Cook, David Miller, Barbara Cipriani, Anthony J. Good, PhD Read more - https://lnkd.in/gGQbUjbg To share your startup story write us on - contact@startuprise.co.uk #Pathios #development #innovative #medtech #immunotherapy #biotech #pharmaceutical #funding #fundingnews #startupnews #news #startuprise

Candid Therapeutics represent a new era of biotech NewCos. - Early 2024: After selling RayzeBio to Bristol Myers Squibb for $4.1B, former CEO Ken Song launches Candid in stealth, builds a management team and starts looking for drugs to build a biotech around. - Aug 5 2024: TCR 2004 is launched by Third Rock Ventures and Two River with an undisclosed funding round and pays $XXM upfront + >$400M milestone payments to Genor BioPharma to license (ex-China) a bispecific T-cell engager to test in autoimmunity. - Sep 3 2024: Vignette Bio, incubated by Foresite Labs, licenses (ex-China) a phase 1 stage T-cell engager bispecific from EpimAb Biotherapeutics, Inc. for $60M + >$500M milestone payments for use in autoimmune diseases. - Sep 9 2024: Candid Therapeutics debuts, announcing both a merger with Vignette and TCR 2004 to develop these drugs under one roof, as well as a $206M raise of its own. The company now has 2 phase 1 ready bispecific t-cell engagers to test in autoimmune diseases and a combined cash haul of >$370M with many high profile investors on board. Release: https://lnkd.in/g34kTVKG